Lipoprotein(a), the rediscovered risk factor, or how to get "back to the future"

Pierre Sabouret; Denis Angoulvant; Kausik K Ray

doi:10.1016/j.acvd.2020.03.008

Lipoprotein(a), the rediscovered risk factor, or how to get "back to the future"

Arch Cardiovasc Dis. 2020 Mar;113(3):147-151. doi: 10.1016/j.acvd.2020.03.008. Epub 2020 Mar 20.

Authors

Pierre Sabouret¹, Denis Angoulvant², Kausik K Ray³

Affiliations

¹ Heart Institute, Pitié-Salpétrière Hospital, ACTION-Group, Pierre and Marie Curie University, 47-83 boulevard de L'Hôpital, 75013 Paris, France. Electronic address: cardiology.sabouret@gmail.com.
² Department of Cardiology, CHRU de Tours and EA4245 T2i, Loire Valley Cardiovascular Collaboration, Tours University, 37000 Tours, France.
³ Department of Public Health, Imperial College, W6 8RP London, UK.

PMID: 32205042
DOI: 10.1016/j.acvd.2020.03.008

No abstract available

Keywords: AKCEA-APO(a)-L(Rx); AKCEA-APO(a)-LRX; Inhibiteurs des PCSK9; Lipid-lowering treatments; Lipoprotein(a); Lp(a); PCSK9 inhibitors; Residual risk; Risque résiduel; Traitements hypolipémiants.

Publication types

Editorial

MeSH terms

Animals
Biomarkers / blood
Cardiovascular Diseases / blood*
Cardiovascular Diseases / diagnosis
Cardiovascular Diseases / epidemiology
Cardiovascular Diseases / prevention & control
Dyslipidemias / blood*
Dyslipidemias / diagnosis
Dyslipidemias / drug therapy
Dyslipidemias / epidemiology
Humans
Hypolipidemic Agents / therapeutic use
Lipoprotein(a) / blood*
Prognosis
Risk Factors
Up-Regulation

Substances

Biomarkers
Hypolipidemic Agents
Lipoprotein(a)